Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Thiosulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiosulfuric Acid SCHEMBL11025255 | 0.95 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL27794360 | 0.95 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL167560 | 0.95 | — | — | |
| Thiosulfuric Acid SCHEMBL9814396 | 0.95 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL3692401 | 0.90 | MEN1 (0.36) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL3698555 | 0.90 | MEN1 (0.36) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL9104325 | 0.90 | MEN1 (0.36) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL7904303 | 0.90 | — | — | |
| Thiosulfuric Acid SCHEMBL4626957 | 0.90 | MEN1 (0.36) | MEN1ALDH1A1TSHRKMT2A | |
| Thiosulfuric Acid SCHEMBL3691097 | 0.90 | MEN1 (0.36) | MEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047050-A1 | PERSONAL ANTIMICROBIAL CARRIER | PAC X, LLC | 2022-02-17 | — | — | US | disclosed |
| WO-2022036259-A1 | PERSONAL ANTIMICROBIAL CARRIER | PAC X, LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-9480260-B2 | Acrylic polymers containing metallic nanoparticles | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140288171-A1 | ACRYLIC POLYMERS CONTAINING METALLIC NANOPARTICLES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2014-09-25 | — | — | US | disclosed |
| US-8779023-B2 | In situ formation of nanoparticles in resins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-15 | — | — | US | disclosed |
| US-8425880-B1 | Metal-containing materials for treatment of bacterial conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-23 | — | — | US | disclosed |
| US-20130095184-A1 | Metal-Containing Materials for Treatment of Bacterial Conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20110306699-A1 | IN SITU FORMATION OF NANOPARTICLES IN RESINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-12-15 | — | — | US | disclosed |
| EP-1575552-A2 | METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS | Nucryst Pharmaceuticals Corp. (CA) | 2005-09-21 | — | — | EP | disclosed |
| EP-1567101-A2 | PROPHYLACTIC TREATMENT METHODS | NUCFRYST PHARMACEUTICALS CORP. (CA) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005074949-A1 | TREATMENT OF UNGUAL AND SUBUNGUAL DISEASES WITH ANTIMICROBIAL METAL COMPOSITIONS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2005-08-18 | — | — | WO | disclosed |
| US-20040191329-A1 | Compositions and methods of metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-30 | — | — | US | disclosed |
| US-20040176312-A1 | Treatment of ungual and subungual diseases | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-09 | — | — | US | disclosed |
| US-20040131698-A1 | Methods of treating conditions using metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040129112-A1 | Metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040110738-A1 | Prophylactic treatment methods | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-06-10 | — | — | US | disclosed |
| WO-2004037187-A2 | METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037186-A2 | PROPHYLACTIC TREATMENT METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288171-A1 | ACRYLIC POLYMERS CONTAINING METALLIC NANOPARTICLES | CAD, PUF60, CD63 | MEN1 1997/4885ALDH1A1 1351/4885TSHR 4830/4885 |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | MEN1 1564/4885ALDH1A1 1712/4885TSHR 170/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | MEN1 2291/4885ALDH1A1 1842/4885TSHR 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.